BEIJING, Nov. 4, 2009 (Xinhua News Agency) -- Sinovac Biotech (AMEX:SVA) Ltd. (SVA.AMEX), a leading Chinese vaccine producer, announced Wednesday it got the green light to transfer its listing from the AMEX to the NASDAQ.

It expects to start trading on the NASDAQ in mid-November, with the ticker code SVA. Sinovac is the only Chinese vaccine producer listed on the US stock market.

Amid soaring demand for H1N1 flu vaccines, China's vaccine market will see growing potentials, said Yin Weidong, chairman and president of Sinovac.

By transferring the listing to the NASDAQ, Sinovac wishes to get more funding for its research and development in vaccines, output expansion and merger and acquisition moves.

The listing on NASDAQ shows the company's ability to meet the requirements of the NASDAQ, he said. The transferring to the NASDAQ, one of the most influential stocks trading market, will attract more attention from investors and analysts.